{"id":550655,"date":"2026-02-10T13:43:56","date_gmt":"2026-02-10T13:43:56","guid":{"rendered":"https:\/\/www.capgemini.com\/au-en\/?p=550655&#038;preview=true&#038;preview_id=550655"},"modified":"2026-02-10T13:44:11","modified_gmt":"2026-02-10T13:44:11","slug":"jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation","status":"publish","type":"post","link":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/","title":{"rendered":"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation"},"content":{"rendered":"\n<header class=\"wp-block-cg-blocks-hero-blogs header-hero-blogs\"><div class=\"container\"><div class=\"hero-blogs\"><div class=\"hero-blogs-content-wrapper\"><div class=\"row\"><div class=\"col-12\"><div class=\"header-title\"><h1>JPM Healthcare 2026: Signals shaping the next era of life sciences innovation<\/h1><\/div><\/div><\/div><\/div><div class=\"hero-blogs-bottom\"><div class=\"header-author\"><div class=\"author-img\"><img decoding=\"async\" src=\"\/wp-content\/themes\/capgemini2025\/assets\/images\/cg-logo-white.svg?w=200&amp;quality=10\" alt=\"\" loading=\"lazy\"\/><\/div><div class=\"author-name-date\"><h5 class=\"author-name\">Capgemini<\/h5><h5 class=\"blog-date\">Feb 10, 2026<\/h5><\/div><\/div><div class=\"brand-image\"><\/div><\/div><\/div><\/div><\/header>\n\n\n\n<section class=\"wp-block-cg-blocks-intro-para section section--intro\"><div class=\"intro-para\"><div class=\"container\"><div class=\"row\"><div class=\"col-12 col-md-1\"><nav class=\"article-social\"><ul class=\"social-nav\"><li class=\"ip-order-fb\"><a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https:\/\/www.capgemini.com\/au-en\/?p=550655\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"opens in a new window\"><i aria-hidden=\"true\" class=\"icon-fb\"><\/i><span class=\"sr-only\">Facebook<\/span><\/a><\/li><li class=\"ip-order-li\"><a href=\"https:\/\/www.linkedin.com\/sharing\/share-offsite\/?url=https:\/\/www.capgemini.com\/au-en\/?p=550655\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"opens in a new window\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><span class=\"sr-only\">Linkedin<\/span><\/a><\/li><\/ul><\/nav><\/div><div class=\"col-12 col-md-11 col-lg-10\"><h2 class=\"intro-para-title\">Each year, JPM Week serves as one of the industry\u2019s most reliable barometers, revealing not only where the life sciences industry stands today, but where it is heading next.<\/h2><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-group section section--article-content\"><div class=\"article-main-content\"><div class=\"container\"><div class=\"row\"><div class=\"col-12 col-md-11 col-lg-10 offset-md-1 offset-lg-1\"><div class=\"article-text article-quote-text\">\n<p>While this year\u2019s event brought fewer major announcements, it revealed clear signs of an industry in transition as shifts within the business, technology and scientific landscape converge. &nbsp;As organizations look ahead, success will depend on strategies that intentionally balance all three, aligning commercial priorities, digital capabilities, and scientific advancement to navigate the year ahead with clarity and confidence.<\/p>\n\n\n\n<p>Here our experts share their key takeaways from JPM Week 2026 and what they mean for life sciences companies as they navigate a world of multi-dimensional change.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-1-m-amp-a-is-heating-up-china-is-emerging-as-an-innovation-hub-and-growth-constraints-remain\">1. <strong>M&amp;A is heating up, China is emerging as an innovation hub, and growth constraints remain.<\/strong><\/h4>\n\n\n\n<p>Even without the usual stack of announcements, JPM Week revealed a clear undercurrent across leadership conversations: M&amp;A is about to pick up.<\/p>\n\n\n\n<p>After a period of caution, biopharma organizations are once again viewing partnerships, targeted acquisitions, and ecosystem expansion as critical levers to accelerate innovation. Over the next 18-24 months, we expect to see companies doubling down on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pipeline acceleration through targeted innovation plays<\/li>\n\n\n\n<li>Strategic partnerships to access new modalities<\/li>\n\n\n\n<li>Ecosystem collaborations enabling scale and speed<\/li>\n<\/ul>\n\n\n\n<p>In a market increasingly shaped by specialty therapies, chronic disease management, and patient-centric service models, M&amp;A is emerging as an essential enabler of growth.<\/p>\n\n\n\n<p>There are also clear signals that investments, partnerships and M&amp;A activity is shifting to China, as the country solidifies its position as both an innovation hotbed and major source of novel therapeutics. Recent announcements such as <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/fierce-biotechs-jpm26-tracker-day-2\">Novartis paying $50 million in cash<\/a> for a China-based biotech program and <a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2026\/astrazeneca-invests-15bn-in-china-through-2030.html\">AstraZeneca committing &nbsp;investments of $15 billion<\/a> in China through 2030, serve as broader industry tell-tales of China as both an innovation hub and critical commercial market.<\/p>\n\n\n\n<p>Finally, stubborn growth constraints remain, with intensified scrutiny on drug pricing, reimbursement, and market access across regions. This underscored the idea that success will hinge not just on scientific breakthroughs, but on navigating increasingly complex regulatory environments and volatile pricing markets.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-2-ai-moves-from-experimentation-to-essential-infrastructure-especially-in-r-amp-d\">2. <strong>AI moves from experimentation to essential Infrastructure, especially in R&amp;D.<\/strong><\/h4>\n\n\n\n<p>Perhaps the most significant shift at JPM 2026 was the universal recognition that AI has now clearly crossed the threshold from proof-of-concept (PoC) into operational reality.<\/p>\n\n\n\n<p>This was felt not just in the specific industry sessions, but everywhere in San Francisco. We heard about AI, genAI and agentic AI as commodities you need to adopt at scale. Likewise, AI\u2011driven robotics and deep\u2011tech engineering are no longer futuristic, they are being adopted at an accelerated pace.<\/p>\n\n\n\n<p>In life sciences, these broader tech trends are manifesting in the following ways:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>AI has become a core driver of R&amp;D productivity, with the greatest multiplier effects emerging in drug discovery. This was seen most clearly through partnership announcements between <a href=\"https:\/\/nvidianews.nvidia.com\/news\/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai\">NVIDIA and Lilly for a co-innovation lab<\/a> and <a href=\"https:\/\/www.fiercebiotech.com\/medtech\/thermo-fisher-scientific-teams-nvidia-tetrascience-next-gen-ai-workflow-projects\">Thermo Fisher Scientific\u2019s partnership with NVIDIA<\/a> to build out its autonomous laboratory infrastructure.<\/li>\n\n\n\n<li>Use cases have matured and proven clear outcomes, with tangible value in cycle-time reduction and PoC optimization;<\/li>\n\n\n\n<li>Expectations for stakeholder engagement, including doctors, patient and payers, are soaring.<\/li>\n<\/ul>\n\n\n\n<p>This shift is setting a new benchmark for what \u201cinnovation-ready\u201d organizations look like. This holds particularly decisive at a time where pharma is adding new modalities, such as RNA medicines, cell therapies, and gene therapies beyond the traditional paradigm of small molecules and antibodies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-3-the-evolving-role-of-pharma-in-care-delivery\">3. The evolving role of pharma in care delivery.<\/h4>\n\n\n\n<p>Beyond R&amp;D, conversations this year reflected a broader point: the role of pharma in care is changing. Growth in obesity treatments and new therapeutic modalities was accompanied by increased interest in direct-to-patient (DTP) models.<\/p>\n\n\n\n<p>Further, the launches of <a href=\"https:\/\/openai.com\/index\/introducing-chatgpt-health\/\">ChatGPT Health<\/a> and <a href=\"https:\/\/www.anthropic.com\/news\/healthcare-life-sciences\">Claude for Healthcare<\/a> just before this year\u2019s conference, as well as the recent emergence of players such as <a href=\"https:\/\/ro.co\/\">Ro<\/a> or <a href=\"https:\/\/www.hims.com\/about\/the-company\">Hims &amp; Hers<\/a>, are not coincidences. Rather they reflect the same shift on the technology side\u2014offering AI-enabled health tools for patients and caregivers to strengthen education, engagement and intervention.<\/p>\n\n\n\n<p>DTP has moved beyond experimentation, with pharma accelerating the build-out of new technical and organizational capabilities to manage the end-to-end patient experience\u2014from initial exploration through medical decision support and care delivery. This comes with an opportunity for pharma companies to build deep proprietary data assets.<\/p>\n\n\n\n<p>Despite pricing pressure and regulatory uncertainty, innovation in this space remains vibrant. Companies are experimenting with new ways to engage, support, and empower patients, creating a more integrated care ecosystem. As this space evolves, it is possible that the patient will reclaim more power within the health journey and that the care system will have to accommodate this new normal.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-4-the-reshaping-of-therapeutic-areas-and-geographies-of-interest\">4. The reshaping of therapeutic areas and geographies of interest.<\/h4>\n\n\n\n<p>While oncology remains a key therapeutic area of focus, with companies developing novel therapies targeting various cancer types, neuroscience is gaining traction, as companies explore treatments for neurodegenerative diseases and mental health disorders. Novo and Lilly are also paving the way in addressing cardiometabolic diseases, such as obesity and diabetes, with new drugs and approaches.<\/p>\n\n\n\n<p>Beyond traditional markets like the U.S., Europe and Japan, companies are also focused on expanding into Asia and also emerging economies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-inside-jpm-week-collaboration-dialogue-and-production-ready-innovation\">Inside JPM Week: Collaboration, dialogue, and production\u2011ready innovation<\/h3>\n\n\n\n<p>Capgemini was deeply involved throughout JPM Week, contributing across client sessions, industry roundtables, and leadership discussions. A standout moment was our JPM Detox Breakfast at the Applied Innovation Exchange, which brought together more than 300 people across pharma, medtech, startups and industry.<\/p>\n\n\n\n<p><strong>Program highlights included:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A fireside chat with Salesforce\u2019s Sharmin Nasrullah and Capgemini\u2019s Barnab\u00e9 Lecouteux which explored how Salesforce is leveraging its CRM stronghold to reshape the clinical operations paradigm.<\/li>\n\n\n\n<li>Dr. Ashutosh Saxena\u2019s perspective and fireside chat with Andreas Sjostrom and John Robbins on the rise of physical AI, including the concept of connected buildings as intelligent robotic systems.<\/li>\n\n\n\n<li>Ready-to-deploy deep tech demos with Cambridge Consultants spanning generative AI for surgery (powered by NVIDIA), microchip-level DNA sequencing, and AI-enabled bioengineering.<\/li>\n\n\n\n<li>A demonstration from Insilico Medicine\u2019s Petrina Kamya, PhD, showcasing our joint work on agentic systems built on Pharmaceutical Superintelligence (PSI) and domain-specific LLMs.<\/li>\n<\/ul>\n\n\n\n<p>We also unveiled our latest research &nbsp;on the state of R&amp;D in pharma at Fierce Pharma\u2019s JPM Week: <a href=\"https:\/\/www.capgemini.com\/fi-en\/insights\/research-library\/how-ai-will-transform-life-sciences-r-and-d\/\"><em>Smart bet, only option, or both?: Biopharma R&amp;D turns to AI.<\/em><\/a>This report presents new research from the Capgemini Research Institute about how AI is reshaping drug discovery, clinical trials, and regulatory processes\u2014and what leaders must do to scale its impact.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-looking-ahead-jpm-2027-and-beyond\">Looking ahead: JPM 2027 and beyond<\/h3>\n\n\n\n<p>The sentiment across San Francisco was unmistakable: organizations that pair bold strategic moves with meaningful AI adoption will set the pace for the next era of healthcare innovation. Others are at risk of being disrupted.<\/p>\n\n\n\n<p>We were encouraged by feedback from colleagues, partners, and clients who noted the visibility and impact of our capabilities across R&amp;D, digital transformation, and emerging technologies.<\/p>\n\n\n\n<p>Now, with JPM 2026 officially behind us, we focus on the future. The coming year promises rapid evolution in digital health, next-generation modalities, AI\u2011driven R&amp;D, and patient\u2011centric service models.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-one-question-remains-across-all-areas-how-can-companies-ensure-that-patients-reap-the-greatest-benefits-from-these-r-evolutions\">One question remains across all areas: How can companies ensure that patients reap the greatest benefits from these (r)evolutions?<\/h4>\n<\/div><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"section section--expert-slider wrapper-people-slider wp-block-cg-blocks-wrapper-people-slider\"><div class=\"container\"><div class=\"content-title\"><h2 data-maxlength=\"34\" class=\"people-heading-title\">Authors<\/h2><\/div><\/div><div class=\"slider slider-boxed\"><div class=\"container\"><div class=\"slider-window\"><div class=\"slider-list\">\t\t<div class=\"slide\">\n\t\t\t<div class=\"box\">\n\t\t\t\t<div class=\"row\">\n\t\t\t\t\t<div class=\"col-md-6 col-lg-4 box-img-wrapper\">\n\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2024\/02\/Thorsten-Rall-002.jpg\" alt=\"Thorsten Rall\"\/>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div class=\"col-md-6 col-lg-8 box-inner\">\n\t\t\t\t\t\t<div class=\"row title-social-media-header\">\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 mbl-social-icon\">\n\t\t\t\t\t\t\t\t<ul class=\"social-nav\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li><a aria-label=\"Linkedin\" target=\"_blank\" title=\"Opens in a new window\" href=\"https:\/\/www.linkedin.com\/in\/thorsten-alexander-rall-b232185\/\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><\/a><\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 box-container\">\n\t\t\t\t\t\t\t\t<div class=\"box-title\">\n\t\t\t\t\t\t\t\t\t<h3 class=\"people-profile-title\">Thorsten Rall<\/h3>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span>Global Industry Lead Life Sciences, EVP<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 social-box-container dkt-social-icon\">\n\t\t\t\t\t\t\t\t<ul class=\"social-nav\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li><a aria-label=\"Linkedin\" target=\"_blank\" title=\"Opens in a new window\" href=\"https:\/\/www.linkedin.com\/in\/thorsten-alexander-rall-b232185\/\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><\/a><\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"people-info\">Since January 2023, Thorsten has been the Executive Vice President and Global Industry Lead for Life Sciences at Capgemini. Previously, he worked at Novartis in various senior roles. As Senior Vice President of Digital Transformation &#038; Innovation, he led the digital function, developed and implemented high-risk, high-return strategic innovation initiatives, and was responsible for Business Development and partnerships in the digital space. <\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\n\n\t\t<div class=\"slide\">\n\t\t\t<div class=\"box\">\n\t\t\t\t<div class=\"row\">\n\t\t\t\t\t<div class=\"col-md-6 col-lg-4 box-img-wrapper\">\n\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2022\/09\/Rob-Pears-2-e1600168089619-1.jpg\" alt=\"Rob Pears\"\/>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div class=\"col-md-6 col-lg-8 box-inner\">\n\t\t\t\t\t\t<div class=\"row title-social-media-header\">\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 mbl-social-icon\">\n\t\t\t\t\t\t\t\t<ul class=\"social-nav\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li><a aria-label=\"Linkedin\" target=\"_blank\" title=\"Opens in a new window\" href=\"https:\/\/www.linkedin.com\/in\/rob-pears-158a255\/\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><\/a><\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 box-container\">\n\t\t\t\t\t\t\t\t<div class=\"box-title\">\n\t\t\t\t\t\t\t\t\t<h3 class=\"people-profile-title\">Rob Pears<\/h3>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span>Expert in End User Services<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 social-box-container dkt-social-icon\">\n\t\t\t\t\t\t\t\t<ul class=\"social-nav\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li><a aria-label=\"Linkedin\" target=\"_blank\" title=\"Opens in a new window\" href=\"https:\/\/www.linkedin.com\/in\/rob-pears-158a255\/\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><\/a><\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\n\n\t\t<div class=\"slide\">\n\t\t\t<div class=\"box\">\n\t\t\t\t<div class=\"row\">\n\t\t\t\t\t<div class=\"col-md-6 col-lg-4 box-img-wrapper\">\n\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2022\/01\/LECOUTEUX-Barnabe-Perso-1.jpg\" alt=\"Barnab\u00e9 Lecouteux\"\/>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div class=\"col-md-6 col-lg-8 box-inner\">\n\t\t\t\t\t\t<div class=\"row title-social-media-header\">\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 mbl-social-icon\">\n\t\t\t\t\t\t\t\t<ul class=\"social-nav\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li><a aria-label=\"Linkedin\" target=\"_blank\" title=\"Opens in a new window\" href=\"https:\/\/www.linkedin.com\/in\/barnab\u00e9-lecouteux-a9a31ba\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><\/a><\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 box-container\">\n\t\t\t\t\t\t\t\t<div class=\"box-title\">\n\t\t\t\t\t\t\t\t\t<h3 class=\"people-profile-title\">Barnab\u00e9 Lecouteux<\/h3>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span>Vice President, Global Head of Life Sciences Incubator, Capgemini Invent\u200b<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"col-md-12 col-lg-6 social-box-container dkt-social-icon\">\n\t\t\t\t\t\t\t\t<ul class=\"social-nav\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li><a aria-label=\"Linkedin\" target=\"_blank\" title=\"Opens in a new window\" href=\"https:\/\/www.linkedin.com\/in\/barnab\u00e9-lecouteux-a9a31ba\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><\/a><\/li>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"people-info\">With 16 years of experience, Barnab\u00e9 is a seasoned leader in strategy, data, and operations in Life Sciences. Before Capgemini, he worked at Ipsen Pharma as Director of Strategic Planning and at Air Liquide Healthcare, where he was BU Head in Renal Care and Digital Strategy Director for chronic diseases. At Capgemini, he leads the Life Sciences incubator for Invent, focusing on Data and AI services in R&#038;D. He is the author of the Capgemini annual barometer \u201cAI for Health\u201d and delivers regular thought leadership on Data and AI in the sector.<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div><\/div><\/div><div class=\"slider-nav\"><button class=\"slider-prev inactive\" aria-label=\"Slider-previous\" tabindex=\"-1\"><\/button><ul class=\"slider-paginator\"><\/ul><button class=\"slider-next\" aria-label=\"Slider-next\"><\/button><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>JPM Healthcare 2026 revealed a sector at a strategic inflection point. While headline announcements were fewer, the signals were louder: M&#038;A is returning with purpose, AI has firmly crossed into production\u2011grade infrastructure, and pharma\u2019s role in care delivery is rapidly expanding. The conversations across San Francisco made one thing clear\u2014leaders who align business strategy, intelligent technology, and scientific advancement will define the next decade of healthcare innovation. Everyone else risks being left behind.<\/p>\n","protected":false},"author":699,"featured_media":550656,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"cg_dt_proposed_to":[],"cg_seo_hreflang_relations":"[]","cg_seo_canonical_relation":"","cg_seo_hreflang_x_default_relation":"","cg_dt_approved_content":true,"cg_dt_mandatory_content":false,"cg_dt_notes":"","cg_dg_source_changed":true,"cg_dt_link_disabled":false,"_yoast_wpseo_primary_brand":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","featured_focal_points":""},"categories":[1],"tags":[],"brand":[],"service":[139],"industry":[36],"partners":[],"blog-topic":[461],"content-group":[],"class_list":["post-550655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","service-intelligent-business-operations","industry-life-sciences","blog-topic-people-experience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.8 (Yoast SEO v22.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>JPM Healthcare 2026: Signals shaping the next era of life sciences innovation - Capgemini Australia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation\" \/>\n<meta property=\"og:description\" content=\"JPM Healthcare 2026 revealed a sector at a strategic inflection point. While headline announcements were fewer, the signals were louder: M&amp;A is returning with purpose, AI has firmly crossed into production\u2011grade infrastructure, and pharma\u2019s role in care delivery is rapidly expanding. The conversations across San Francisco made one thing clear\u2014leaders who align business strategy, intelligent technology, and scientific advancement will define the next decade of healthcare innovation. Everyone else risks being left behind.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Capgemini Australia\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T13:43:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T13:44:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2025\/10\/New-Web-preview-global.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Capgemini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"elishavalekar\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/\",\"url\":\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/\",\"name\":\"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation - Capgemini Australia\",\"isPartOf\":{\"@id\":\"https:\/\/www.capgemini.com\/au-en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg\",\"datePublished\":\"2026-02-10T13:43:56+00:00\",\"dateModified\":\"2026-02-10T13:44:11+00:00\",\"author\":{\"@id\":\"https:\/\/www.capgemini.com\/au-en\/#\/schema\/person\/d5a00e336d198ead20a92fc1ca50cc2b\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#primaryimage\",\"url\":\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg\",\"contentUrl\":\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg\",\"width\":5120,\"height\":2880,\"caption\":\"Female Research Scientist with Bioengineer Working on a Personal Computer with Screen Showing Virus Analysis Software User Interface. Scientists Developing Vaccine, Drugs and Antibiotics in Laboratory\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.capgemini.com\/au-en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.capgemini.com\/au-en\/#website\",\"url\":\"https:\/\/www.capgemini.com\/au-en\/\",\"name\":\"Capgemini Australia\",\"description\":\"Capgemini\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.capgemini.com\/au-en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.capgemini.com\/au-en\/#\/schema\/person\/d5a00e336d198ead20a92fc1ca50cc2b\",\"name\":\"elishavalekar\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.capgemini.com\/au-en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ddbecdbccdad1dd8b32a065814a45d631db326b06e3c1682c69cf1356da99377?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ddbecdbccdad1dd8b32a065814a45d631db326b06e3c1682c69cf1356da99377?s=96&d=mm&r=g\",\"caption\":\"elishavalekar\"},\"url\":\"https:\/\/www.capgemini.com\/au-en\/author\/elishavalekar\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation - Capgemini Australia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/","og_locale":"en_US","og_type":"article","og_title":"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation","og_description":"JPM Healthcare 2026 revealed a sector at a strategic inflection point. While headline announcements were fewer, the signals were louder: M&A is returning with purpose, AI has firmly crossed into production\u2011grade infrastructure, and pharma\u2019s role in care delivery is rapidly expanding. The conversations across San Francisco made one thing clear\u2014leaders who align business strategy, intelligent technology, and scientific advancement will define the next decade of healthcare innovation. Everyone else risks being left behind.","og_url":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/","og_site_name":"Capgemini Australia","article_published_time":"2026-02-10T13:43:56+00:00","article_modified_time":"2026-02-10T13:44:11+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2025\/10\/New-Web-preview-global.jpg","type":"image\/jpeg"}],"author":"Capgemini","twitter_card":"summary_large_image","twitter_misc":{"Written by":"elishavalekar","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/","url":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/","name":"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation - Capgemini Australia","isPartOf":{"@id":"https:\/\/www.capgemini.com\/au-en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#primaryimage"},"image":{"@id":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg","datePublished":"2026-02-10T13:43:56+00:00","dateModified":"2026-02-10T13:44:11+00:00","author":{"@id":"https:\/\/www.capgemini.com\/au-en\/#\/schema\/person\/d5a00e336d198ead20a92fc1ca50cc2b"},"breadcrumb":{"@id":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#primaryimage","url":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg","contentUrl":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg","width":5120,"height":2880,"caption":"Female Research Scientist with Bioengineer Working on a Personal Computer with Screen Showing Virus Analysis Software User Interface. Scientists Developing Vaccine, Drugs and Antibiotics in Laboratory"},{"@type":"BreadcrumbList","@id":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.capgemini.com\/au-en\/"},{"@type":"ListItem","position":2,"name":"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation"}]},{"@type":"WebSite","@id":"https:\/\/www.capgemini.com\/au-en\/#website","url":"https:\/\/www.capgemini.com\/au-en\/","name":"Capgemini Australia","description":"Capgemini","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.capgemini.com\/au-en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.capgemini.com\/au-en\/#\/schema\/person\/d5a00e336d198ead20a92fc1ca50cc2b","name":"elishavalekar","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.capgemini.com\/au-en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ddbecdbccdad1dd8b32a065814a45d631db326b06e3c1682c69cf1356da99377?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ddbecdbccdad1dd8b32a065814a45d631db326b06e3c1682c69cf1356da99377?s=96&d=mm&r=g","caption":"elishavalekar"},"url":"https:\/\/www.capgemini.com\/au-en\/author\/elishavalekar\/"}]}},"blog_topic_info":[{"id":461,"name":"People experience"}],"taxonomy_info":{"category":[{"id":1,"name":"Uncategorized","slug":"uncategorized"}],"service":[{"id":139,"name":"Intelligent business operations","slug":"intelligent-business-operations"}],"industry":[{"id":36,"name":"Life sciences","slug":"life-sciences"}],"blog-topic":[{"id":461,"name":"People experience","slug":"people-experience"}],"following_users":[{"id":466,"name":"elishavalekar","slug":"elishavalekar"},{"id":376,"name":"shilpasingh","slug":"shilpasingh"}]},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation","url":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/"},"thumbnailUrl":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg?w=150&h=150&crop=1","image":{"@type":"ImageObject","url":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg"},"articleSection":"Uncategorized","author":[],"creator":[],"publisher":{"@type":"Organization","name":"Capgemini Australia","logo":""},"keywords":[],"dateCreated":"2026-02-10T13:43:56Z","datePublished":"2026-02-10T13:43:56Z","dateModified":"2026-02-10T13:44:11Z"},"rendered":"<meta name=\"parsely-title\" content=\"JPM Healthcare 2026: Signals shaping the next era of life sciences innovation\" \/>\n<meta name=\"parsely-link\" content=\"https:\/\/www.capgemini.com\/au-en\/insights\/expert-perspectives\/jpm-healthcare-2026-signals-shaping-the-next-era-of-life-sciences-innovation\/\" \/>\n<meta name=\"parsely-type\" content=\"post\" \/>\n<meta name=\"parsely-image-url\" content=\"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg?w=150&amp;h=150&amp;crop=1\" \/>\n<meta name=\"parsely-pub-date\" content=\"2026-02-10T13:43:56Z\" \/>\n<meta name=\"parsely-section\" content=\"Uncategorized\" \/>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/capgemini.com\/p.js"},"jetpack_featured_media_url":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg","archive_status":false,"featured_image_src":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg","featured_image_alt":"","jetpack_sharing_enabled":true,"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"Capgemini Australia","distributor_original_site_url":"https:\/\/www.capgemini.com\/au-en","push-errors":false,"featured_image_url":"https:\/\/www.capgemini.com\/au-en\/wp-content\/uploads\/sites\/10\/2026\/02\/Hero-VI-Detox-Breakfast-event.jpg","_links":{"self":[{"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/posts\/550655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/users\/699"}],"replies":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/comments?post=550655"}],"version-history":[{"count":1,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/posts\/550655\/revisions"}],"predecessor-version":[{"id":550659,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/posts\/550655\/revisions\/550659"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/media\/550656"}],"wp:attachment":[{"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/media?parent=550655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/categories?post=550655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/tags?post=550655"},{"taxonomy":"brand","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/brand?post=550655"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/service?post=550655"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/industry?post=550655"},{"taxonomy":"partners","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/partners?post=550655"},{"taxonomy":"blog-topic","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/blog-topic?post=550655"},{"taxonomy":"content-group","embeddable":true,"href":"https:\/\/www.capgemini.com\/au-en\/wp-json\/wp\/v2\/content-group?post=550655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}